Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab with Chemotherapy and Chemoradiation in Locally Advanced Esophageal Adenocarcinoma
NCT02998268Phase 2Active, not recruiting
- Sponsor
- Weill Cornell Medicine
- Start
- Mar 2017
- Primary completion
- Feb 2021
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab in esophageal adenocarcinoma (EAC) (2 cohorts), sponsored by Weill Cornell Medicine. Primary endpoint: Major Pathological Response. Started Mar 2017; status: active, not recruiting.
02
Drugs
03
Conditions
esophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT02998268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02998268.